Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TLOG +35%
TLOG-Roth $5 PT target today
NVET $3.90-Broadfin 6% 13G came out yesterday as well. one to watch for sure.
TNXP-breaking $7.13 could be big breakout, This company was over $18-$19 few years ago now they the data coming soon and enrollment complete, could be a huge play in 2016
TNXP-Big catalysts lined up for 2016 quarter after quarter. Last run up it went over $10 very fast. Chart is shaping up well and big year ahead for this company for sure.
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache --------Top-line Results Q1
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) ----------- Top-line Results Q2
TNXP-Huge catalysts lined up for 2016 one quarter after another. Last runup it went over $10 very fast. Chart is shaping up well and big year ahead for this company for sure.
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache --------Top-line Results Q1
Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) ----------- Top-line Results Q2
CBAY-Partnership and results from Phase 2 in the deck early 2016. Partnership should give a significant boost to the share price imo. Cash is about $2 per share imo.
CBAY-Catalysts coming up on this one. They're waiting for partnership could come in January or so and then results from phase 2 i believe. Cash is about $2 per share
GBIM +14% volume came towards the end of the day. There was a seeking alpha released also
GBIM-Potential Reverse Merger or buyout candidate imo. They hired Cantor Fitzgerald on August 13 for strategic options.
They have stated: "We have engaged Cantor Fitzgerald & Co. to explore alternative ways to maximize stockholder value, including transactions involving the merger or sale of all or part of our assets. "
http://finance.yahoo.com/news/globeimmune-engages-cantor-fitzgerald-financial-103000791.html
CBAY $1.58 on the rise on good volume
TNXP-"Sleep Improvement for Fibromyalgia Sufferers Possible, Study Shows" http://nationalpainreport.com/sleep-improvement-for-fibromyalgia-sufferers-possible-study-shows-8828334.html
TNXP-"Sleep Improvement for Fibromyalgia Sufferers Possible, Study Shows" http://nationalpainreport.com/sleep-improvement-for-fibromyalgia-sufferers-possible-study-shows-8828334.html
OCRX $3.35-This one will be a good play in 2016 ! Good price to add. imo.
RTTR-really like this one, baker bros own this one and mkt cap same as cash.
KBIO explode-RTTR major play tomorrow imo. People will be looking for low float stocks and RTTR also has baker bros
CALA inching up again, looks like nice entry here
RTTR~Solid DD ash.
SPHS big win-RTTR trying to pick up some more. I agree this could be next.Trading at cash value ?
RTTR volume increasing past few days,looks like accumulation
BIND-$5.10 BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents
http://finance.yahoo.com/news/bind-presents-data-demonstrating-ability-173000424.html
BIND-moving on "BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents"
http://finance.yahoo.com/news/bind-presents-data-demonstrating-ability-173000424.html
RTTR-picking up some here today at $2.30
RTTR $2.32 Aegis out with $7 PT
NVET $5.70 +8% again today
RTTR, $7 PT by Aegis today ?
NVET $5.20 going up again, this low floater has continuous buyer
CBAY $1.65 CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11
MNOV will present interim results today
MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida
http://finance.yahoo.com/news/medicinova-announces-interim-data-clinical-110000913.html
NVET $5.15 +10% again, low floater with cash about ~ $4.77 per share, multiple catalysts on deck, cheap low float name that could really spike imo.
NVET $4.6-slow grinding up, trading at cash value, multiple catalysts on deck, LOW Float. One to watch for volume imo.
FATE strong again on a red day like this.
FATE +24% on solid volume. Looks like it bottomed out. Low floater.
FATE +24% could be big mover. Low float and bottom prices
OXGN $1.02 definitely strong with good volume.
PIRS $1.86 took a long position here today. Agree the selling seems almost over. This was over $3 not too long ago.
DYAI positive trial news with sanofi